Evidence map›Paper›PMID 33871333›Full record

ArticleTurkish thoracic journal2021

Comparative Analysis of Three Different Drug Distribution Schemes for Smoking Cessation.

Banu Salepci, Sevda Özdoğan, Elif Çiğdem Altunok, Tuba Naziroğlu, Nesrin Kıral, Elif Torun Parmaksız, Ali Fidan, Seda Beyhan Sağmen, Coşkun Doğan, Sevda Sener Cömert

Abstract read
In one paragraph

Article in Turkish thoracic journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Banu SalepciDepartment of Chest Diseases, Yeditepe University School of Medicine, İstanbul, Turkey.
Sevda ÖzdoğanDepartment of Chest Diseases, Yeditepe University School of Medicine, İstanbul, Turkey.
Elif Çiğdem AltunokDepartment of Biostatistics and Medical Informatics, Yeditepe University School of Medicine, İstanbul, Turkey.
Tuba NaziroğluDepartment of Chest Diseases, Health Sciences University Kartal Dr. Lütfi Kırdar Education and Research Hospital, İstanbul, Turkey.
Nesrin KıralDepartment of Chest Diseases, Health Sciences University Kartal Dr. Lütfi Kırdar Education and Research Hospital, İstanbul, Turkey.
Elif Torun ParmaksızDepartment of Chest Diseases, Health Sciences University Kartal Dr. Lütfi Kırdar Education and Research Hospital, İstanbul, Turkey.
Ali FidanDepartment of Chest Diseases, Health Sciences University Kartal Dr. Lütfi Kırdar Education and Research Hospital, İstanbul, Turkey.
Seda Beyhan SağmenDepartment of Chest Diseases, Health Sciences University Kartal Dr. Lütfi Kırdar Education and Research Hospital, İstanbul, Turkey.
Coşkun DoğanDepartment of Chest Diseases, Health Sciences University Kartal Dr. Lütfi Kırdar Education and Research Hospital, İstanbul, Turkey.
Sevda Sener CömertDepartment of Chest Diseases, Health Sciences University Kartal Dr. Lütfi Kırdar Education and Research Hospital, İstanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to compare the success rate of 3 different drug prescription policies: Free drugs with online system prescription, free drugs with doctor's prescription, and drugs paid for by patients with doctor's prescription. MATERIAL AND

methodsThe effect of 2 different Ministry of Health (MoH) projects with free-of-charge and self-payment pharmacotherapies for smoking cessation were compared. Patients who completed 6 months of pharmacotherapy and follow-up were evaluated. The first period was free-of-charge medication, which was determined by an online system, the following period was the self-payment period, and the third period was free medication, which was prescribed by a doctor. In all the groups, smoking habits in pack years and comorbidities of the patients were recorded, and pulmonary function tests (PFTs) and expiratory carbon dioxide (CO2) measurements were performed. Patients who had an expiratory CO2 level >5 ppm at the control visits were accepted as quitters.

resultsA total of 829 patients with 438 patients in the first free-of-charge period (group 1), 111 in the self-payment period (group 2), and 280 in the second free-of-charge period (group 3) were enrolled in the study. Smoking cessation rates were significantly higher in the self-payment medication group (25%) according to the MoH's free-of-charge project groups. There was no difference in smoking cessation rates between the 2 free-of-charge medication project groups (15% in group 1 and 11% of group 3). Among all the patients, we compared 124 patients who quit smoking with 705 patients who did not. The quitters were older, mostly male, and heavier smokers. In addition, the number of patients with chronic obstructive pulmonary disease and obstructive PFT rates were higher among the quitters. Their dependency score, PFTs, and the use of free medication was lower, and treatment duration was longer. Independent factors that increased smoking cessation success were longer treatment duration, lower dependency score, and self-payment of medication.

conclusionFree medications provided via 2 different modalities did not increase the smoking cessation success. Paying for the medication, lower dependency score, and longer treatment duration increased smoking cessation success independently.

Identifiers

PMID33871333
PMCPMC8051300

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.